https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=10343
No pharmaceutical opinion available for this interaction.
Darunavir / ritonavir can inhibit the CYP 3A4 and P-gp and increase the plasma concentration of Ticagrelor.
Darunavir / ritonavir can inhibit the metabolism (CYP 3A4) and decrease the active metabolite formation of Ticagrelor.
–
–
Antiretrovirals that do not inhibit or induce CYP3A4, such as bictegravir, dolutegravir, or doravirine.
Possible decrease of clinical efficacy.
Possible increase of adverse effects.
Contraindicated. Use alternative.
Prasugrel (Efficient)
Adverse effects of ticagrelor: Bleeding (epistaxis, gastrointestinal/cutaneous hemorrhage), bruising, dyspnea, headache, dizziness, gastrointestinal effects (nausea, vomiting, dyspepsia, diarrhea or constipation), bradycardia.
–
–
Ref #3164 : An in vitro study with healthy volunteers showed that ketoconazole, a potent inhibitor of CYP3A4, increased ticagrelor AUC by more than 7.3-fold and Cmax by 2.4-fold and decreased the active metabolite AUC and Cmax by 56% and 89%, respectively.